StockGlow

BioArctic AB (publ) (BIOA-B.ST)

Develops antibody drugs to treat Alzheimer's, Parkinson's, and other brain diseases

325.40+0.01%Healthcare
Compare BIOA-B.ST with
StockGlow Score
67
Leaning Bullish
BearishBullish
1 year ago+55.5%

The outlook

BioArctic trades at 325.4 SEK, sitting well above both its 50- and 200-day moving averages and three-quarters of the way up its 52-week range. Analyst consensus leans toward Hold with mixed coverage; the average price target sits roughly 7% below the current level. The stock's valuation is notably elevated at a P/E of 137, reflecting investor expectations in this small-cap biotech name.

What’s behind the score

Analyst consensusHold — 2.8 avg of 5 analysts
Price trendAbove its 50- & 200-day averages
52-week range76% of the way from its 52-week low to high
Price targetAvg target -7% vs current price

Analyst price target

~12-month · 5 analysts
301.40average target-7.4% vs now
Now 325.40
Low 240.00High 363.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$28.87B
52-wk high
364.40
52-wk low
204.60
50-day avg
314.01
200-day avg
312.97
Trailing P/E
137.3

Similar stocks

CAMX.STCamurus AB (publ)$625.00+0.24%ONCO.STOncopeptides AB (publ)$1.62+0.68%BONEX.STBonesupport Holding AB (publ)$219.80+2.33%SOBI.STSwedish Orphan Biovitrum AB (publ)$470.40+0.77%BIOG-B.STBioGaia AB (publ)$114.10-1.04%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy